2026-04-29T04:52:14Zhttps://repisalud.isciii.es/rest/oai/requestoai:repisalud.isciii.es:20.500.12105/227002024-11-29T00:07:36Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16967col_20.500.12105_16983
Repisalud
author
Montero, Maria M
author
Domene-Ochoa, Sandra
author
López-Causapè, Carla
author
VanScoy, Brian
author
Luque, Sonia
author
Sorli, Luisa
author
Campillo, Nuria
author
Padilla, Eduardo
author
Prim, Nuria
author
Segura, Concepcion
author
Pomar, Virginia
author
Rivera, Alba
author
Grau, Santiago
author
Ambrose, Paul G
author
Oliver, Antonio
author
Horcajada, Juan P
2024-09-10T13:08:53Z
2024-09-10T13:08:53Z
2019-09
Montero Maria M., Domene Ochoa Sandra, López-Causapè Carla, Vanscoy Brian, Luque Sonia, Sorli Luisa, et al. Colistin plus meropenem combination is synergistic in vitro against extensively drug-resistant Pseudomonas aeruginosa, including high-risk clones. J Glob Antimicrob Resist. 2019 Sep;18:37-44. Epub 2019 May 30.
2213-7165
http://hdl.handle.net/20.500.13003/15231
https://hdl.handle.net/20.500.12105/22700
31154007
10.1016/j.jgar.2019.04.012
2213-7173
Journal of Global Antimicrobial Resistance
2-s2.0-85067395021
485661700007
L2002134467
Background: Extensively drug-resistant (XDR) Pseudomonas aeruginosa (P. aeruginosa) and particularly P. aeruginosa high-risk clones, are of growing concern because treatment options are limited. For years, colistin monotherapy has been the only available treatment, but is well known that is not an optimal treatment. A combination of colistin with another antibiotic could be a possible therapeutic option. Objectives: This study aimed to investigate effective antibiotic combinations against 20 XDR P. aeruginosa isolates obtained in a Spanish multicentre study (2015). Methods: Forty-five checkerboards with six antipseudomonal antibiotics (amikacin, aztreonam, ceftazidime, meropenem, colistin, and ceftolozane/tazobactam) were performed to determine whether combinations were synergic or additive by fractional inhibitory concentration indices. On average, 15 different regimens were evaluated in duplicate against the three most prevalent high-risk clones (ST175, ST235, ST111) by time-kill analyses over 24 h. The combination showing synergism in the three high-risk clones was validated in all studied XDR isolates. Results: In time-kill curves, the untreated control failed, as did each study regimen when administered alone. Two combinations were synergistic in the three high-risk clones that were initially studied: amikacin plus ceftazidime and colistin plus meropenem, with the second being the most effective combination. The efficacy of colistin plus meropenem was then tested in all 20 isolates. A synergistic bacterial density reduction for the duration of the study occurred in 80% of the entire XDR collection. Conclusions: These data suggest that colistin plus meropenem may be a useful combination for the treatment of infections due to XDR P. aeruginosa, including high-risk clones, which warrants evaluation in a clinical trial.
eng
Colistin
Meropenem
Combination therapy
Pseudomonas aeruginosa
Synergy
Colistin plus meropenem combination is synergistic in vitro against extensively drug-resistant Pseudomonas aeruginosa, including high-risk clones
research article